Healthpeak Properties enters the final week of June with the defensive posture from a week ago unwinding — shorts are covering, options are calming down, and JP Morgan just raised its target the morning this note was filed.
The most important development since last week's note is the sharp short interest reversal. SI peaked near 28 million shares on June 15 and has now fallen 26% over the past week to roughly 3% of the free float — the lowest level in over a month. That unwind is meaningful context: the prior note flagged the June 15 spike as noise, and that read has proved correct. The covering trend is now broad and consistent across every session since June 16. Borrow conditions reinforce the picture — cost to borrow eased to 0.49% from 0.58% a week ago, and availability is exceptionally loose at nearly 5,000% of short interest. There is no squeeze dynamic here, and no sign of fresh conviction on the short side.
Options positioning has also eased from last week's elevated reading. The put/call ratio has pulled back to 0.45 from the 0.49 level that drove the prior note's defensive framing — still above the 20-day average of 0.35, but the z-score has dipped to 1.15 standard deviations. That's no longer an alerting signal. The cautious tone in options hasn't disappeared, but it has moderated alongside the short covering.
The Street is sending a clearer signal than it was a week ago. JP Morgan's Michael Mueller raised his price target this morning from $18 to $21 while keeping a Neutral rating — the move matters because it comes from a bellwether firm and puts his target above the current $20.56 price. BMO Capital lifted its target to $24 earlier in the week, maintaining Outperform, representing the most constructive call in the recent cluster. Against that, Morgan Stanley downgraded to Equal-Weight on June 11, raising its target to $22 while stepping back from Overweight — a classic "raise and fade" that captures the tension in the consensus. The overall rating remains Hold, with 12 analysts sitting on the fence, but the direction of target revisions is clearly upward across the board. The EV/EBITDA multiple has eased roughly 1% over the past month to 14.5x, offering modest valuation support. The EPS surprise factor score ranks in the 99th percentile — the company has been a consistent beat, even if growth expectations remain muted.
Institutional ownership is stable and heavily indexed. BlackRock holds 10.6% and JP Morgan Asset Management recently added nearly 12 million shares, bringing its stake to 4.7% — the most notable active move in the holder list. That build-up at JPM AM adds an interesting layer given this morning's analyst target raise from the same firm's research desk. The insider activity from late May — a cluster of small token sales by the CEO and several EVPs on the same day — carries no weight at these sizes and significance scores of 1.
The next earnings print is August 4. The stock jumped roughly 19% the day after its last two results, suggesting the market has been using these events as re-rating moments rather than routine updates. With short interest now more than 40% lower than a month ago and analysts steadily lifting targets, the setup heading into that release looks more constructive than it did in mid-June — but the gap between the Hold consensus and the bullish outliers on the Street is the tension worth watching as that date approaches.
See the live data behind this article on ORTEX.
Open DOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
